Efficacy and safety study of continuous paravertebral block with PCA to inhibit the chronicity of herpes zoster-associated neuralgia: a prospective randomized controlled clinical trial

INTERVENTION: Experimental group:Continuous paravertebral nerve block;Control group:Repetitive paravertebral nerve block; CONDITION: herpes zoster PRIMARY OUTCOME: Pain degree 1 month after treatment; SECONDARY OUTCOME: Incidence of PHN (disease duration > 90 days, VAS > 30) after 2 months;VAS score, PSQI score, PHQ‐9 score and GAD‐7 score before treatment, 1 week, 2 weeks, 3 weeks, 1 month and 2 months after treatment;Proportion of patients with complete pain relief (VAS=10), good sleep quality (PSQI=10), no anxiety (PHQ‐9=4) and no depression (GAD‐7=4) before treatment, 1, 2, 3, 1 and 2 weeks after treatment;Dosage of analgesic drugs and remedial drugs;Occurrence of adverse reactions and serious adverse events; INCLUSION CRITERIA: 1.HZ diagnostic criteria were met, and the VAS score was =40 at the time of consultation 2.Age =18 years and =85 years 3.The extent of herpes lesions was in the area of thoracic spinal innervation (T1‐T12), involving =4 segments, and the duration of the disease was 30‐90 days 4.No nerve block or other minimally invasive interventions were received before enrollment 5.Consent to participate in this study and sign the informed consent form